CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 77.3% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Bristol Myers BMY

BristolMyers live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

BristolMyers news

Magnificent 7 earnings, US and Japan inflation due next week
Neil Wilson 2024 Jul 18, 16:00

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Forex Indices
Wall Street earnings
Neil Wilson 2023 Oct 20, 10:00

Week ahead: Earnings bonanza, ECB decision & US inflation

Forex Indices
Megacap-tech-stocks.jpg
Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

2022 Jul 24, 05:42

Week ahead: Fed to hike 100bps into a recession?

Laatste marktnieuws

Toon meer
Ghko B 2025 Jun 11, 16:00

Crypto Market Sentiment: Crypto Fear and Greed Index Today

Cryptocurrencies
Tommy Yap 2025 Jun 11, 16:00

Morning Note: Adobe’s AI Momentum Leads Market Moves with Gold and Fed in Focus

Morning Note Gold Commodities Stocks
Ghko B 2025 Jun 10, 16:00

BTC USD Price Prediction: How much will Bitcoin be worth in 2030?

Cryptocurrencies
Ghko B 2025 Jun 10, 16:00

Wells Fargo Stock Slides 1.32%: Is Wells Fargo stock a good buy now?

Stocks
Tommy Yap 2025 Jun 10, 16:00

Morning Note: U.S. CPI, Japan Inflation Shape Market Expectations Today

Morning Note USD JPY S&P 500
Darius Anucauskas 2025 Jun 10, 16:00

Morning Note: Trade Truce, CPI Data Put Fed and Markets in Spotlight

Morning Note DJIA CPI Forex
Ghko B 2025 Jun 09, 16:00

Latest 2025 BTC Price Predictions: Will Bitcoin Hit $150K?

Cryptocurrencies
Ghko B 2025 Jun 09, 16:00

Most Active Japanese Stocks: SONY, TAK, HMC, Toyota Motor, TOELY

Stocks

Info

Spread

0.31

Spread (%)

0.6205 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Donderdag

13:31 - 19:59

Maandag

13:31-19:59

Dinsdag

13:31-19:59

Woensdag

13:31-19:59

Vrijdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

101692948480

Uitstaande aandelen

2035079936

Datum winstcijfer (volgende)

2001-08-07

Div. rend.

2025-05-01

Ex-dividenddatum

2025-04-04

Jaarlijks verwachte dividendpercentage

2.48

Jaarlijks verwachte dividendrendement

0.0506

Winst per aandeel

2.68

Meer informatie over dit instrument

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten

latest_education_articles

Toon meer
Trustpilot